BTIG Reaffirms Celgene (CELG) at 'Buy'; Q3 Results, Update Bolster Confidence

October 28, 2016 11:30 AM EDT
Get Alerts CELG Hot Sheet
Price: $112.66 -0.84%

Rating Summary:
    28 Buy, 8 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CELG Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BTIG affirms Celgene Corporation (Nasdaq: CLEG) at Buy with a price target of $138 following Q3 results and update.

The firm commented today: Full-year 2016 EPS guidance moved up +$0.17 at the midpoint, above the +$0.10 3Q16 EPS beat, and highlighted Sales and EPS for 2017 should trend towards the higher end of the prior guidance ranges. We reiterate our Buy rating and $138PT as management commentary for key clinical and commercial catalysts should increase investor optimism for 2017.

For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View

Related Entities


Add Your Comment